Company & Sponsor Intelligence

AbbVie (prior sponsor, Abbott)

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed2

Countries1

Therapeutic footprint

adhdalzheimersparkinsons

Indexed studies

NCT01690195Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT00360568Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
parkinsons · United StatesPHASE3

NCT00640185Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →